<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Couto JP</submitter><funding>European Molecular Biology Organization</funding><funding>Swiss National Science Foundation</funding><funding>European Research Council</funding><funding>Promedica Stiftung</funding><funding>H2020 Marie Skłodowska-Curie Actions</funding><funding>Krebsliga Schweiz</funding><funding>Novartis</funding><pagination>e112559</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10308372</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(13)</volume><pubmed_abstract>Metastatic colonization of distant organs accounts for over 90% of deaths related to solid cancers, yet the molecular determinants of metastasis remain poorly understood. Here, we unveil a mechanism of colonization in the aggressive basal-like subtype of breast cancer that is driven by the NAD&lt;sup>+&lt;/sup> metabolic enzyme nicotinamide N-methyltransferase (NNMT). We demonstrate that NNMT imprints a basal genetic program into cancer cells, enhancing their plasticity. In line, NNMT expression is associated with poor clinical outcomes in patients with breast cancer. Accordingly, ablation of NNMT dramatically suppresses metastasis formation in pre-clinical mouse models. Mechanistically, NNMT depletion results in a methyl overflow that increases histone H3K9 trimethylation (H3K9me3) and DNA meth</pubmed_abstract><journal>The EMBO journal</journal><pubmed_title>Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer.</pubmed_title><pmcid>PMC10308372</pmcid><funding_grant_id>F‐87701‐41‐01</funding_grant_id><funding_grant_id>841872</funding_grant_id><funding_grant_id>694033</funding_grant_id><pubmed_authors>Schmidt A</pubmed_authors><pubmed_authors>Obradovic MM</pubmed_authors><pubmed_authors>Frei AL</pubmed_authors><pubmed_authors>Ivanek R</pubmed_authors><pubmed_authors>Mertz KD</pubmed_authors><pubmed_authors>Koelzer VH</pubmed_authors><pubmed_authors>Varga Z</pubmed_authors><pubmed_authors>Jehanno C</pubmed_authors><pubmed_authors>Sethi A</pubmed_authors><pubmed_authors>Hamelin B</pubmed_authors><pubmed_authors>Manivannan M</pubmed_authors><pubmed_authors>Gomez-Miragaya J</pubmed_authors><pubmed_authors>Couto JP</pubmed_authors><pubmed_authors>Vulin M</pubmed_authors><pubmed_authors>Bentires-Alj M</pubmed_authors><pubmed_authors>Coissieux MM</pubmed_authors><pubmed_authors>Brautigam K</pubmed_authors><pubmed_authors>Hager C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer.</name><description>Metastatic colonization of distant organs accounts for over 90% of deaths related to solid cancers, yet the molecular determinants of metastasis remain poorly understood. Here, we unveil a mechanism of colonization in the aggressive basal-like subtype of breast cancer that is driven by the NAD&lt;sup>+&lt;/sup> metabolic enzyme nicotinamide N-methyltransferase (NNMT). We demonstrate that NNMT imprints a basal genetic program into cancer cells, enhancing their plasticity. In line, NNMT expression is associated with poor clinical outcomes in patients with breast cancer. Accordingly, ablation of NNMT dramatically suppresses metastasis formation in pre-clinical mouse models. Mechanistically, NNMT depletion results in a methyl overflow that increases histone H3K9 trimethylation (H3K9me3) and DNA meth</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jul</publication><modification>2026-06-01T20:25:44.96Z</modification><creation>2026-05-20T03:08:11.455Z</creation></dates><accession>S-EPMC10308372</accession><cross_references><pubmed>37259596</pubmed><doi>10.15252/embj.2022112559</doi></cross_references></HashMap>